staceywhite, Author at European Medical Journal - Page 162 of 194

Allergen-Specific Immunotherapy

Allergen-specific immunotherapy remains the only causal treatment of allergic disease to date. Its efficacy in symptom reduction was demonstrated in…

Management of Cardiovascular Risk Factors in Type 2 Diabetes Mellitus Patients

People with Type 2 diabetes mellitus (T2DM), compared with non-diabetic individuals, have increased cardiovascular risk. Part of this excess risk is…

Role of Coagulation Factor Concentrates in the Operating Room

The use of fresh frozen plasma, cryoprecipitate, and platelets has been the mainstay of approaches to correct coagulopathies that can arise in the…

Gene Delivery from Stents for Prevention of In-Stent Restenosis

The increasing sophistication of vascular stent design, especially devices that combine mechanical support with local drug delivery to the vascular wall…

Revolution of Drug-Eluting Coronary Stents: An Analysis of Market Leaders

Percutaneous coronary intervention with drug-eluting stents (DES) is a well-established and widely-accepted treatment approach in patients with coronary…

Sepsis-Induced Immune Paralysis Reversed by β-Glucan

SEPSIS is a life-threatening condition with inefficient treatment options available at present. With an incidence of approximately 2–30 per 10,000 people…

Association Found Between Vitamin D Levels and Breast Cancer Prognosis

VITAMIN D serum biomarker levels, particularly 25-hydroxyvitamin D, can be used to gauge vitamin deficiency or abundance among patients. In 2003 alone…

Enzyme Deficiency Provides New Treatment Target for Prader-Willi Syndrome

DEFICIENCY of the prohormone covertase (PC1) enzyme in the brain has been linked to the neuro-hormonal abnormalities found in patients with Prader-Willi…

Molecular Signature of Liver Disease Indicates Responsiveness to First-Line Therapy

SCIENTISTS have shown how high-risk primary biliary cholangitis (PBC), or PBC in patients who do not respond to conventional treatment, has distinct…

Promising Drug Trial Results for Infant Spinal Muscular Atrophy Treatment

THE INTERIM results of a small, ongoing Phase II trial have shown that the drug nusinersen is a well-tolerated treatment for infantile-onset spinal…